Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Universite Claude Bernard – Lyon1

Ecole Normale Superieure De Lyon

Biofocus Discovery Limited

Bundersrepublik Deutschland, Letzvertreten Durch Den Präsidenten Des Paul-ehrlich-instituts

Bundesrepublik Deutschland, Letztvertreten Durch Den Prasidenten Des Paul-ehrlich-instituts

Paul-ehrlich-institut Bundesamt Fur Sera Und Impfstoffe

Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-ehrlich-instituts Prof. Dr. Klaus Cichutek

Christian Buchholz

Roberto Cattaneo

Klaus Cichutek

Stephen James Russell

Els Verhoeyen

Mark P Chadwick

François-Loïc Cosset

Gerald Schumann

Sabrina Kneissl

Caroline Costa Fejoz

Qi Zhou

Sabrina Funke

Ruben Bender

Tobias Abel

Patricia Bach

Irene Schneider

Sabine Klawitter

The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.

Nipah virus envelope glycoprotein pseudotyped lentivirus

The invention relates to the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family, genus, and various uses of the resulting vector particles. The present invention is based on the unexpected and surprising finding that the incorporation ofF and H proteins having truncated cytoplasmic tails into lentiviral vector particles, and the complex interaction of these two proteins during cellular fusion, allows for a superior and more effective transduction of cells. Moreover, these pseudotyped vector particles allow the targeted gene transfer into a given cell type of interest by modifying a mutated and truncated H protein with a single-chain antibody or ligand directed against a cell surface marker of the target cell.

Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high throughput screening

Methods are disclosed whereby protease activity is directly linked to delivery of a transferable label to a target cell which expresses a protease, via fusion of viral display packages comprising the transferable label with the target cell. The methods can be used, inter alia, to identify proteases, including previously undiscovered proteases or variants of known proteases which may have altered substrate specificity.

Methods and compositions for identifying a polynucleotide encoding a protease

Growing community of inventors

Frankfurt-am-Main, Germany

Christian Buchholz